MODAVAR PHARMACEUTICALS Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • MODAVAR PHARMACEUTICALS's estimated annual revenue is currently $5.4M per year.(i)
  • MODAVAR PHARMACEUTICALS's estimated revenue per employee is $201,000

Employee Data

  • MODAVAR PHARMACEUTICALS has 27 Employees.(i)
  • MODAVAR PHARMACEUTICALS grew their employee count by -10% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13.7M31-14%N/AN/A
#2
$7.2M366%N/AN/A
#3
$17.7M8840%N/AN/A
#4
$28.7M1435%N/AN/A
#5
$1.4M7N/AN/AN/A
#6
$15.3M761%N/AN/A
#7
$596.4M29679%N/AN/A
#8
$5.4M27-10%N/AN/A
#9
$86.8M4327%N/AN/A
#10
$5M254%N/AN/A
Add Company

What Is MODAVAR PHARMACEUTICALS?

Modavar Pharmaceuticals (www.modavar.com) is the US Subsidiary of Cadila Pharmaceutical Group. Cadila Pharmaceuticals Ltd. (www.cadilapharma.com) is one of the largest privately held pharmaceutical companies in the world. Over the past six decades, Cadila has been developing and manufacturing affordable medicines for patients around the world with presence in 7 countries including the United States. Cadila has a full range of CGMP compliant manufacturing services for prescription pharmaceuticals. Its state-of-the-art facilities are USFDA approved, as well as by WHO Geneva, UK MHRA, TGA Australia, MCC South Africa, ANVISA Brazil. Cadila’s innovation-led drug discovery processes ensure the health and well-being of people around the world. Its enhanced investment in innovation, combined with a strong track record in research and development, has made a profound impact on patient lives. Being a care-focused, research-driven company, Cadila is committed to complying with the highest ethical standard in clinical research.

keywords:N/A

N/A

Total Funding

27

Number of Employees

$5.4M

Revenue (est)

-10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3M27-46%$36.4M
#2
$2.7M27N/AN/A
#3
$1.9M27-31%$32.5M
#4
$4.7M27N/AN/A
#5
$4.8M27N/AN/A